EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS
August 02 2024 - 1:30AM
UK Regulatory
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC
TEST FROM MYRIAD GENETICS
EUROBIO SCIENTIFIC COMPLETES ACQUISITION
OF ENDOPREDICT®
GENOMIC TEST FROM MYRIAD GENETICS
Paris, August
2nd, 2024 –7:30
am
Eurobio Scientific
(FR0013240934, ALERS), a leading French group in in vitro
specialty medical diagnostics and life sciences, announces the
finalisation of its agreement with Myriad Genetics to acquire the
EndoPredict® genomic test.
As part of the agreement announced on 7 May 2024
(see press release below), on 1 August 2024 the Group has completed
the acquisition of the second-generation genomic test EndoPredict®
for breast cancer and the license agreement to distribute the
second-generation genomic test Prolaris® for prostate cancer from
Myriad Genetics. Revenues from these two activities are around €8m
on an annual basis, with EBITDA levels in the short and medium term
diluting the Group's performance.
To see the press release dated May
7th, 2024, click here.
About Eurobio Scientific
Eurobio Scientific is a key player in the field of specialty in
vitro diagnostics. It is involved from research to manufacturing
and commercialization of diagnostic tests in the fields of
transplantation, immunology and infectious diseases, and sells
instruments and products for research laboratories, including
biotechnology and pharmaceutical companies. Through many
partnerships and a strong presence in hospitals, Eurobio Scientific
has established its own distribution network and a portfolio of
proprietary products in the molecular biology field. The Group has
approximately 290 employees and four production units based in the
Paris region, in Germany, in the Netherlands and in the United
States, and several affiliates based in Dorking UK, Sissach
Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The
Netherlands and Milan in Italy.
Eurobio Scientific's reference shareholder is the EurobioNext
holding company which brings together its two directors,
Jean-Michel Carle and Denis Fortier, alongside the "Pépites et
Territoires" by AXA & NextStage AM investment program, managed
by NextStage AM.
For more information, please visit: www.eurobio-scientific.com
The company is publicly listed on the Euronext Growth market in
Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech
indices, Euronext European Rising Tech label.
Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA -
Bloomberg: ALERS:FP
|
Contacts |
Groupe Eurobio Scientific
Denis Fortier, Chairman and CEO
Olivier Bosc, Deputy CEO / CFO
Tel. +33(0) 1 69 79 64 80 |
Calyptus
Mathieu Calleux
Investors Relations
Tel. +33(1) 53 65 68 68 - eurobio-scientific@calyptus.net |
- 240802PR_Eurobio Scientific_Finalisation_EndoPredict_EN
(2)
Eurobio Scientific (EU:ALERS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Eurobio Scientific (EU:ALERS)
Historical Stock Chart
From Nov 2023 to Nov 2024
